Ladhani Salma, Empringham Brianna, Wang Kuan-Wen, Portwine Carol, Banfield Laura, de Souza Russell J, Thabane Lehana, Samaan M Constantine
Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.
Division of Pediatric Endocrinology, McMaster Children's Hospital, Hamilton, Ontario, Canada.
BMJ Open. 2018 Jun 22;8(6):e022530. doi: 10.1136/bmjopen-2018-022530.
Acute lymphoblastic leukaemia is the most common paediatric cancer. Survivors of childhood acute lymphoblastic leukaemia (SALL) are at risk of obesity and related cardiometabolic diseases including type 2 diabetes, hypertension, stroke and cardiovascular events. Therefore, it is important to address obesity in this population as this may help mitigate future cardiometabolic comorbidities. In this systematic review, we aim to assess current treatment strategies including lifestyle interventions, pharmacotherapy and bariatric surgery to manage overweight and obesity in SALL.
We will search the following databases for primary studies: CINAHL, SPORTDiscus, EMBASE, MEDLINE, PsycINFO, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews. In addition, unpublished primary studies will be searched in ClinicalTrials.gov as well as conference proceedings, presentations, abstracts, editorials and ProQuest Dissertations and Theses A&I. Reviewers will perform title, abstract, and full-text screening as well as data abstraction and risk of bias assessment independently with a third reviewer to be consulted to resolve disagreements. Searches will be run and updated through May 1st, 2018. The overall quality of the evidence will be determined using the Grading of Recommendations, Assessment, Development, and Evaluation criteria for each outcome. A meta-analysis will be performed if two studies deploying similar interventions, populations, and design and outcomes are identified.
As individual patient data will not be included, we do not require ethics approval. This review will be published in a peer-reviewed journal.
CRD42016051031.
急性淋巴细胞白血病是最常见的儿科癌症。儿童急性淋巴细胞白血病幸存者(SALL)有肥胖及相关心脏代谢疾病的风险,包括2型糖尿病、高血压、中风和心血管事件。因此,解决该人群的肥胖问题很重要,因为这可能有助于减轻未来的心脏代谢合并症。在本系统评价中,我们旨在评估当前包括生活方式干预、药物治疗和减肥手术在内的治疗策略,以管理SALL患者的超重和肥胖问题。
我们将在以下数据库中检索原始研究:护理学与健康领域数据库(CINAHL)、体育与运动医学数据库(SPORTDiscus)、荷兰医学文摘数据库(EMBASE)、医学索引数据库(MEDLINE)、心理学文摘数据库(PsycINFO)、Cochrane对照试验中心注册库以及Cochrane系统评价数据库。此外,还将在ClinicalTrials.gov以及会议论文集、报告、摘要、社论和ProQuest学位论文及综合文摘库中检索未发表的原始研究。评审人员将独立进行标题、摘要和全文筛选以及数据提取和偏倚风险评估,如有分歧将咨询第三位评审人员以解决。检索将持续进行并更新至2018年5月1日。将使用推荐分级、评估、制定和评价标准(GRADE)来确定每个结局的证据总体质量。如果识别出两项采用相似干预措施、研究人群、设计和结局的研究,将进行荟萃分析。
由于不纳入个体患者数据,我们无需伦理批准。本评价将发表在同行评审期刊上。
PROSPERO注册号:CRD42016051031。